Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016 - Product Image

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

  • ID: 3783287
  • Report
  • 128 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • Amgen Inc.
  • BioLingus AG
  • HitGen LTD
  • Kymab Limited
  • Merck & Co., Inc.
  • MORE
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016

Summary

‘Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2016’, provides in depth analysis on Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted pipeline therapeutics.

The report provides comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects
- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • Amgen Inc.
  • BioLingus AG
  • HitGen LTD
  • Kymab Limited
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) Overview

Therapeutics Development

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Stage of Development

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Therapy Area

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Indication

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Companies

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Products under Development by Universities/Institutes

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development

Abeome Corporation

AFFiRiS AG

Alnylam Pharmaceuticals, Inc.

Amgen Inc.

Betagenon AB

BioLingus AG

Catabasis Pharmaceuticals, Inc.

Daiichi Sankyo Company, Limited

Eli Lilly and Company

HitGen LTD

Kowa Company, Ltd.

Kymab Limited

MedImmune, LLC

Merck & Co., Inc.

Pfizer Inc.

Planet Biotechnology Inc.

Regeneron Pharmaceuticals, Inc.

Serometrix, LLC

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Thetis Pharmaceuticals LLC

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Drug Profiles

(atorvastatin calcium + TP-452) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

alirocumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-PCSsc - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATH-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATH-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics to Target PCSK-9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bococizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CAT-2000 Series - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DS-9001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

evolocumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KY-1020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3015014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-4166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

O-304 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Coronary Artery Disease and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SX-PCK9 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TP-452 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Dormant Projects

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Discontinued Products

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) - Featured News & Press Releases

Jun 02, 2016: The Medicines Company Completes Patient Enrollment for ORION-1 Study of PCSK9si

May 24, 2016: New Cholesterol Treatment Now Available for Canadians

May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting

May 23, 2016: The Results From A One Year Treatment Of Repatha Presented At The Annual Meeting Of The Japan Diabetes Society

May 16, 2016: ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards

May 11, 2016: Cigna’s New Value-Based Contract with Sanofi/Regeneron for Praluent

May 11, 2016: Cigna’s New Value-Based Contract with Amgen for Repatha

May 06, 2016: Innovative cholesterol-lowering treatment, Praluent (alirocumab), approved by NICE for people with raised cholesterol levels who are at significantly high risk of a heart attack or stroke

May 06, 2016: NICE Sets Out Draft Recommendations For Repatha (Evolocumab) In Final Appraisal Determination

Apr 26, 2016: Bococizumab SPIRE-2 Cardiovascular Outcome Study Fully Enrolled

Apr 21, 2016: Amgen Astellas Biopharma And Astellas Introduce Repatha (Evolocumab) For The Treatment Of High Cholesterol

Apr 04, 2016: New study results of Repatha (evolocumab) in statin-intolerant patients published in Journal of the American Medical Association

Apr 03, 2016: Positive Efficacy And Tolerability Study Of Repatha (evolocumab) In Statin-Intolerant Patients Published In "Journal of the American Medical Association"

Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab

Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Abeome Corporation, H1 2016

Pipeline by AFFiRiS AG, H1 2016

Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Betagenon AB, H1 2016

Pipeline by BioLingus AG, H1 2016

Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016

Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Pipeline by Eli Lilly and Company, H1 2016

Pipeline by HitGen LTD, H1 2016

Pipeline by Kowa Company, Ltd., H1 2016

Pipeline by Kymab Limited, H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Pfizer Inc., H1 2016

Pipeline by Planet Biotechnology Inc., H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016

Pipeline by Serometrix, LLC, H1 2016

Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016

Pipeline by Thetis Pharmaceuticals LLC, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abeome Corporation
  • Amgen Inc.
  • BioLingus AG
  • HitGen LTD
  • Kymab Limited
  • Merck & Co., Inc.
  • MORE
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 30 molecules. Out of which approximately 28 molecules are developed by Companies and remaining by the Universities/Institutes. Our latest report Proprotein Convertase SubtilisinKexin Type 9 – Pipeline Review, H1 2016, outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 3, 5, 10, 6 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Furthermore, this report also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis-Regulated Convertase 1 or PCSK9 or EC 3.4.21.) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
Abeome Corporation
AFFiRiS AG
Alnylam Pharmaceuticals, Inc.
Amgen Inc.
Betagenon AB
BioLingus AG
Catabasis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Eli Lilly and Company
HitGen LTD
Kowa Company, Ltd.
Kymab Limited
MedImmune, LLC
Merck & Co., Inc.
Pfizer Inc.
Planet Biotechnology Inc.
Regeneron Pharmaceuticals, Inc.
Serometrix, LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Thetis Pharmaceuticals LLC
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll